NASDAQ:RPHM Reneo Pharmaceuticals (RPHM) Stock Forecast, Price & News $7.58 +0.49 (+6.91%) (As of 05:12 PM ET) Add Compare Share Share Today's Range$7.00▼$7.9750-Day Range$5.44▼$8.0352-Week Range$1.79▼$11.30Volume104,212 shsAverage Volume116,214 shsMarket Capitalization$256.20 millionP/E RatioN/ADividend YieldN/APrice Target$30.00 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Reneo Pharmaceuticals MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside282.7% Upside$30.00 Price TargetShort InterestBearish10.34% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment1.43Based on 2 Articles This WeekInsider TradingSelling Shares$808,125 Sold Last QuarterProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.87 out of 5 starsMedical Sector710th out of 968 stocksPharmaceutical Preparations Industry321st out of 445 stocks 3.5 Analyst's Opinion Consensus RatingReneo Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $30.00, Reneo Pharmaceuticals has a forecasted upside of 282.7% from its current price of $7.84.Amount of Analyst CoverageReneo Pharmaceuticals has only been the subject of 2 research reports in the past 90 days. Previous Next 0.0 Short Interest Percentage of Shares Shorted10.34% of the float of Reneo Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverReneo Pharmaceuticals has a short interest ratio ("days to cover") of 12.2, which indicates bearish sentiment.Change versus previous monthShort interest in Reneo Pharmaceuticals has recently increased by 16.67%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldReneo Pharmaceuticals does not currently pay a dividend.Dividend GrowthReneo Pharmaceuticals does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for RPHM. Previous Next 3.0 News and Social Media Coverage News SentimentReneo Pharmaceuticals has a news sentiment score of 1.43. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.54 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Reneo Pharmaceuticals this week, compared to 0 articles on an average week.Search InterestOnly 1 people have searched for RPHM on MarketBeat in the last 30 days. This is a decrease of -80% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added Reneo Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -33% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Reneo Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $808,125.00 in company stock.Percentage Held by Insiders17.90% of the stock of Reneo Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions85.01% of the stock of Reneo Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Reneo Pharmaceuticals are expected to remain at ($2.44) per share in the coming year.Price to Earnings Ratio vs. the MarketThe P/E ratio of Reneo Pharmaceuticals is -3.35, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Reneo Pharmaceuticals is -3.35, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioReneo Pharmaceuticals has a P/B Ratio of 1.92. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Reneo Pharmaceuticals (NASDAQ:RPHM) StockReneo Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases. Its lead product candidate is REN001, a potent and selective agonist of the peroxisome proliferator-activated receptor delta that is in clinical development for genetic mitochondrial diseases comprising primary mitochondrial myopathies and long-chain fatty acid oxidation disorders. Reneo Pharmaceuticals, Inc. was incorporated in 2014 and is headquartered in Irvine, California.Read More RPHM Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart RPHM Stock News HeadlinesSeptember 20, 2023 | finance.yahoo.comReneo Pharmaceuticals (NASDAQ:RPHM) Is In A Good Position To Deliver On Growth PlansSeptember 8, 2023 | msn.comHC Wainwright & Co. Reiterates Reneo Pharmaceuticals (RPHM) Buy RecommendationSeptember 22, 2023 | Chaikin Analytics (Ad)This is the #1 Stock to Buy for the AI Tidal WaveMarc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.September 8, 2023 | markets.businessinsider.comH.C. Wainwright Keeps Their Buy Rating on Reneo Pharmaceuticals (RPHM)August 28, 2023 | msn.comHC Wainwright starts Reneo at buy, sees possible 2025 launch for lead drugAugust 28, 2023 | msn.comHC Wainwright & Co. Initiates Coverage of Reneo Pharmaceuticals (RPHM) with Buy RecommendationAugust 10, 2023 | finanznachrichten.deReneo Pharmaceuticals, Inc.: Reneo Pharmaceuticals Reports Second Quarter 2023 Financial ResultsAugust 10, 2023 | finance.yahoo.comReneo Pharmaceuticals, Inc.'s (NASDAQ:RPHM) stock price dropped 10% last week; private equity firms would not be happySeptember 22, 2023 | Weiss Ratings (Ad)Overlooked AI Stock Gets Urgent "Buy"We issued our first "Buy" rating on Apple when it traded at the equivalent of 56 cents per share. It's up 32,571% since. And while Nvidia is up 3x this year… We called it back in 2011. And it has surged 97x (9,624% to be exact) since then. Now, our Weiss Ratings has issued a "Buy" on a stock that's leading the AI revolution in one of the most profitable industries.August 10, 2023 | finance.yahoo.comReneo Pharmaceuticals Reports Second Quarter 2023 Financial ResultsJuly 17, 2023 | msn.comReneo Pharmaceuticals: Promising Potential For PPARδ Agonist, Pending Safety EvaluationJuly 3, 2023 | markets.businessinsider.comReneo Pharmaceuticals (RPHM) Receives a New Rating from Bank of America SecuritiesJune 30, 2023 | finance.yahoo.comReneo Pharmaceuticals to Participate in SVB Securities Therapeutics ForumJune 26, 2023 | finance.yahoo.comReneo Pharmaceuticals Added to Russell 2000® and Russell 3000® IndicesJune 15, 2023 | finance.yahoo.comReneo Pharmaceuticals Announces Presentation and Posters at Mitochondrial Medicine Symposium 2023May 31, 2023 | finance.yahoo.comUpdate -- Reneo Pharmaceuticals to Participate at the Jefferies Healthcare ConferenceMay 31, 2023 | finance.yahoo.comReneo Pharmaceuticals to Participate at the Jefferies Healthcare ConferenceMay 26, 2023 | seekingalpha.comRPHM Reneo Pharmaceuticals, Inc.May 21, 2023 | finance.yahoo.comInsiders Pour $1 Million Each Into These 2 ‘Strong Buy’ Stocks — Here’s Why Wall Street Thinks They Could Double (or More)May 11, 2023 | msn.comReneo Pharmaceuticals: Q1 Earnings InsightsMay 11, 2023 | finanznachrichten.deReneo Pharmaceuticals, Inc.: Reneo Pharmaceuticals Reports First Quarter 2023 Financial ResultsMay 11, 2023 | finance.yahoo.comReneo Pharmaceuticals Reports First Quarter 2023 Financial ResultsMay 9, 2023 | markets.businessinsider.comPiper Sandler Reaffirms Their Buy Rating on Reneo Pharmaceuticals (RPHM)May 4, 2023 | marketwatch.comReneo Pharma Shares Drop 21% After $55M Public Offering PricesMay 4, 2023 | finance.yahoo.comReneo Announces Pricing of Public Offering of Common StockMay 3, 2023 | msn.comReneo Pharmaceuticals launches stock offering, shares fall 10%May 3, 2023 | finance.yahoo.comReneo Pharmaceuticals Announces Proposed Public Offering of Common StockSee More Headlines Receive RPHM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Reneo Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address RPHM Company Calendar Last Earnings8/10/2023Today9/22/2023Next Earnings (Estimated)11/14/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:RPHM CUSIPN/A CIK1637715 Webreneopharma.com Phone858-283-0280FaxN/AEmployees51Year FoundedN/APrice Target and Rating Average Stock Price Forecast$30.00 High Stock Price Forecast$30.00 Low Stock Price Forecast$30.00 Forecasted Upside/Downside+282.7%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($2.34) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-51,960,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-56.76% Return on Assets-51.29% Debt Debt-to-Equity RatioN/A Current Ratio10.65 Quick Ratio10.65 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$4.08 per share Price / Book1.92Miscellaneous Outstanding Shares33,800,000Free Float27,751,000Market Cap$264.99 million OptionableNot Optionable Beta1.14 Investing Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free Report Key ExecutivesMr. Michael G. Grey (Age 70)Founder & Exec. Chairman Comp: $100kMr. Gregory J. Flesher (Age 53)Pres, CEO & Director Comp: $800.45kMr. Michael P. Cruse (Age 51)Chief Operating Officer Comp: $535.47kMs. Ashley F. Hall J.D. (Age 51)Chief Devel. Officer Comp: $661.55kMs. Jennifer P. LamSr. VP of Fin., Principal Financial & Accounting OfficerDr. Alejandro Dorenbaum M.D. (Age 62)Chief Medical Officer Ms. Lynn Purkins Ph.D.Sr. VP of Clinical OperationsMore ExecutivesKey CompetitorsSagimet BiosciencesNASDAQ:SGMTLifecore BiomedicalNASDAQ:LFCRNuvectis PharmaNASDAQ:NVCTAC ImmuneNASDAQ:ACIUVanda PharmaceuticalsNASDAQ:VNDAView All CompetitorsInsiders & InstitutionsTucker Asset Management LLCBought 36,753 shares on 9/8/2023Ownership: 0.109%Ashley HallSold 15,625 sharesTotal: $98,125.00 ($6.28/share)Woodline Partners LPBought 248,000 shares on 8/15/2023Ownership: 0.737%Walleye Capital LLCBought 49,550 shares on 8/15/2023Ownership: 0.147%Citadel Advisors LLCBought 30,524 shares on 8/15/2023Ownership: 0.091%View All Insider TransactionsView All Institutional Transactions RPHM Stock - Frequently Asked Questions Should I buy or sell Reneo Pharmaceuticals stock right now? 2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Reneo Pharmaceuticals in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" RPHM shares. View RPHM analyst ratings or view top-rated stocks. What is Reneo Pharmaceuticals' stock price forecast for 2023? 2 Wall Street analysts have issued 12-month price targets for Reneo Pharmaceuticals' stock. Their RPHM share price forecasts range from $30.00 to $30.00. On average, they anticipate the company's stock price to reach $30.00 in the next twelve months. This suggests a possible upside of 282.7% from the stock's current price. View analysts price targets for RPHM or view top-rated stocks among Wall Street analysts. How have RPHM shares performed in 2023? Reneo Pharmaceuticals' stock was trading at $2.33 at the beginning of 2023. Since then, RPHM shares have increased by 236.5% and is now trading at $7.84. View the best growth stocks for 2023 here. When is Reneo Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 14th 2023. View our RPHM earnings forecast. How were Reneo Pharmaceuticals' earnings last quarter? Reneo Pharmaceuticals, Inc. (NASDAQ:RPHM) announced its earnings results on Thursday, August, 10th. The company reported ($0.65) EPS for the quarter, missing analysts' consensus estimates of ($0.55) by $0.10. When did Reneo Pharmaceuticals IPO? (RPHM) raised $101 million in an initial public offering (IPO) on Friday, April 9th 2021. The company issued 6,300,000 shares at a price of $15.00-$17.00 per share. Jefferies, SVB Leerink and Piper Sandler served as the underwriters for the IPO. What is Reneo Pharmaceuticals' stock symbol? Reneo Pharmaceuticals trades on the NASDAQ under the ticker symbol "RPHM." Who are Reneo Pharmaceuticals' major shareholders? Reneo Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional investors include Carlyle Group Inc. (8.02%), Eventide Asset Management LLC (5.20%), Franklin Resources Inc. (4.00%), Great Point Partners LLC (3.22%), ExodusPoint Capital Management LP (1.65%) and BlackRock Inc. (1.36%). Insiders that own company stock include Ashley Hall, Bali Muralidhar, Gregory J Flesher, Holdings A/S Novo, Michael Cruse, Niall O'donnell, Venture Fund Iii L Rivervest and Vineet R Jindal. View institutional ownership trends. How do I buy shares of Reneo Pharmaceuticals? Shares of RPHM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Reneo Pharmaceuticals' stock price today? One share of RPHM stock can currently be purchased for approximately $7.84. How much money does Reneo Pharmaceuticals make? Reneo Pharmaceuticals (NASDAQ:RPHM) has a market capitalization of $264.99 million. The company earns $-51,960,000.00 in net income (profit) each year or ($2.34) on an earnings per share basis. How can I contact Reneo Pharmaceuticals? The official website for the company is reneopharma.com. The company can be reached via phone at 858-283-0280 or via email at investors@reneopharma.com. This page (NASDAQ:RPHM) was last updated on 9/22/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Reneo Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.